Comparing immunocompetent and immunodeficient mice as animal models for bone tissue engineering

Oral Diseases ◽  
2015 ◽  
Vol 21 (5) ◽  
pp. 583-592 ◽  
Author(s):  
Y Zhang ◽  
X Li ◽  
T Chihara ◽  
T Mizoguchi ◽  
A Hori ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Animal Models ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Immunodeficient Mice

Osteogenic potential of dental and oral derived stem cells in bone tissue engineering among animal models: An update

2021 ◽  
Vol 71 ◽  
pp. 101515
Author(s):  
Antoine Berbéri ◽  
Mohammad Fayyad-kazan ◽  
Sara Ayoub ◽  
Rita Bou Assaf ◽  
Joseph Sabbagh ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Stem Cells ◽  
Animal Models ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Osteogenic Potential

THE IMPORTANCE OF LARGE ANIMAL MODELS FOR TRANSLATIONAL RESEARCH IN BONE TISSUE ENGINEERING

2012 ◽  
Vol 24 (1) ◽  
pp. 287
Author(s):  
S. J. Hollister ◽  
M. B. Wheeler ◽  
S. E. Feinberg ◽  
W. L. Murphy
Keyword(s):  
Tissue Engineering ◽  
Animal Model ◽  
Animal Models ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Large Animal ◽  
Engineering Studies ◽  
Large Animal Models ◽  
Clinical Indications ◽  
Human Situation

The translation of bone tissue engineering (BTE) research to clinical use has been absymal1. Outside of bone void filler biomaterials, only Bone Morphogenetic Protein 2 (BMP2) has made significant inroads to clinical practice, and even BMP2 use has been associated with significant complications including death, dysphagia, and ectopic bone formation. The dearth of BTE products can be attributed to two main causes: (1) the need to develop BTE systems, that successfully integrate scaffolds, growth factors like BMP2 and cells and (2) the need to adapt and implement such systems for a wide variety of clinical indications in CranioMaxilloFacial (CMF), Spine and Orthopedic Surgery. Of course, to fully develop BTE systems (Issue 1) and adapt them to realistic clinical indications, we must be able to test such systems in bone defects that are as close to the human situation as possible. Thus, the use of domestic large animals for bone tissue engineering is critical, as these animals provide challenges in both defect volume and functional loading that can mimic the human situation. In addition, FDA approval for BTE products either through a 510K or IDE/IND/PMA pathway requires the use of a large pre-clinical animal model. However, despite this need, only approximately 60 large animal bone tissue-engineering studies have been published in the past 10 years. Furthermore, NIH has funded only 8% of these studies, and of the 17 bone tissue engineering studies supported by NIH in 2010, only three utilized a large animal model, and none of these used an animal larger than a rabbit. Clearly, increased translation and regulatory approval of BTE therapies will require greater testing in large animal models. We will discuss the current dearth of relevant pre-clinical studies in BTE, and present our work addressing these issues by developing BTE systems (integrated scaffold, growth factor and stem-cell constructs) and testing these systems for realistic clinical applications using the Yorkshire and other swine species as a large pre-clinical animal model. We will detail our work in developing BTE systems for CMF reconstruction and spine fusion in the swine model. Reference Hollister S. J. and Murphy W. L. Scaffold translation: barriers between concept and clinic. Tissue Eng. B. (in press).

scholarly journals Bone Formation by Sheep Stem Cells in an Ectopic Mouse Model: Comparison of Adipose and Bone Marrow Derived Cells and Identification of Donor-Derived Bone by Antibody Staining

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Kristian Kjærgaard ◽  
Chris H. Dreyer ◽  
Nicholas Ditzel ◽  
Christina M. Andreasen ◽  
Li Chen ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Bone Marrow ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Model Comparison ◽  
Osteogenic Potential ◽  
Adherent Cells ◽  
Immunodeficient Mice ◽  
Antibody Staining

Background. Scaffolds for bone tissue engineering (BTE) can be loaded with stem and progenitor cells (SPC) from different sources to improve osteogenesis. SPC can be found in bone marrow, adipose tissue, and other tissues. Little is known about osteogenic potential of adipose-derived culture expanded, adherent cells (A-CEAC). This study comparesin vivoosteogenic capacity between A-CEAC and bone marrow derived culture expanded, adherent cells (BM-CEAC).Method. A-CEAC and BM-CEAC were isolated from five female sheep and seeded on hydroxyapatite granules prior to subcutaneous implantation in immunodeficient mice. The doses of cells in the implants were 0.5 × 106, 1.0 × 106, or 1.5 × 106A-CEAC and 0.5 × 106BM-CEAC, respectively. After eight weeks, bone volume versus total tissue volume (BV/TV) was quantified using histomorphometry. Origin of new bone was assessed using human vimentin (HVIM) antibody staining.Results. BM-CEAC yielded significantly higher BV/TV than any A-CEAC group, and differences between A-CEAC groups were not statistically significant. HVIM antibody stain was successfully used to identify sheep cells in this model.Conclusion. A-CEAC and BM-CEAC were capable of forming bone, and BM-CEAC yielded significantly higher BV/TV than any A-CEAC group.In vitrotreatment to enhance osteogenic capacity of A-CEAC is suggested for further research in ovine bone tissue engineering.

scholarly journals Use of Perfusion Bioreactors and Large Animal Models for Long Bone Tissue Engineering

2014 ◽  
Vol 20 (2) ◽  
pp. 126-146 ◽  
Author(s):  
Leandro S. Gardel ◽  
Luís A. Serra ◽  
Rui L. Reis ◽  
Manuela E. Gomes
Keyword(s):  
Tissue Engineering ◽  
Animal Models ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Long Bone ◽  
Large Animal ◽  
Large Animal Models ◽  
Perfusion Bioreactors
Sign in / Sign up

Export Citation Format

Share Document